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LACTOBACILLUS RHAMNOSUS GG IMPROVES OUTCOME IN 
EXPERIMENTAL PSEUDOMONAS AERUGINOSA PNEUMONIA: 
POTENTIAL ROLE OF REGULATORY T CELLS
Ludmila Khailova, Christine H. Baird, Aubri A. Rush, Eoin N. McNamee, and Paul E. 
Wischmeyer
Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado
Abstract
Introduction—Recent clinical trials show Lactobacillus rhamnosus GG (LGG) administration in 
critical illness has the potential to reduce nosocomial infections and improve clinical outcome. 
However, the mechanism(s) of LGG-mediated benefit following illness and injury remain elusive.
Objective—The aim of this study was to determine the effect of LGG treatment on survival and 
lung injury in a mouse model of Pseudomonas aeruginosa–induced pneumonia. As increased T 
regulatory (Treg) cell numbers have been shown to improve outcome in experimental pneumonia, 
we examined the potential role of Treg cells in probiotic-mediated benefit.
Methods—FVB/N mice were subjected to intratracheal injection of either P. aeruginosa or saline 
and received LGG or vehicle immediately before procedure. T regulatory cell responses in the 
lung were evaluated by polymerase chain reaction, Western blotting, and flow cytometry.
Results—Mice treated with LGG had significantly improved 7-day survival (P < 0.01) compared 
with saline-treated control pneumonia mice (55% LGG vs. 14% control). The survival advantage 
was associated with reduced bacterial counts in bronchoalveolar lavage and with decreased 
markers of the systemic inflammatory response and improved lung pathology in the probiotic 
group. Probiotic treatment influenced immune response in the lungs of mice with pneumonia as 
demonstrated by increased levels of Treg cell marker Foxp3.
Conclusions—These data demonstrate that early administration of LGG improves outcome 
following P. aeruginosa–induced pneumonia. An effect of LGG on Treg cells may play a role in 
this protection.
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INTRODUCTION
Despite advances in antimicrobial therapy and supportive care in critical illness, infection 
and pneumonia remain a common cause of mortality in the United States with more than 
50,000 patients dying of the disease every year (1). Furthermore, in a recent multinational 
intensive care unit (ICU) study of 14,414 patients in 1,265 participating ICUs from 75 
countries, 51% were considered infected on the day of survey, and 71% were receiving 
antibiotics (2). Sixty-four percent of the infections in this study were of respiratory origin, 
and the ICU mortality rate of infected patients was more than twice that of noninfected 
patients (25% vs. 11%, P < 0.001), as was the hospital mortality rate (33% infected vs. 15% 
noninfected, P < 0.001). These data reveal that infection remains a major issue in critical 
care worldwide, leading to significant mortality. Furthermore, antibiotic use occurs in a 
majority (almost three quarters) of all ICU patients. This antibiotic use can lead to 
significant adverse effects, such as overgrowth of indigenous microflora, as well as 
pathogenic bacterial strains, which can be resistant to the standard antimicrobial agents (3).
Specific to ventilator-associated pneumonia (VAP), up to 30% of patients undergoing 
mechanical ventilation acquire VAP, which causes increased morbidity, mortality, and 
prolonged ICU and hospital lengths of stay (4). The pathogenesis of VAP is complex and 
involves colonization of the aerodigestive tract with pathogenic bacteria (4). Preventive 
strategies, such as selective digestion decontamination protocols, have shown some promise 
in preventing respiratory tract infections in the ICU patients; however, clinical use has been 
limited and may be complicated by subsequent bacterial overgrowth of pathogenic bacteria 
(5).
To inhibit or prevent the gastrointestinal colonization and overgrowth by pathogenic 
bacteria, the use of probiotic bacteria has been recently studied. Results from recent 
randomized controlled trials suggest a clinical benefit to the use of probiotics in the ICU (6, 
7). These trials have shown significant reduction of overall infections, particularly VAP (8). 
By definition, probiotics are living nonpathogenic bacteria that colonize the intestine and 
provide a benefit to the host (9). Lactobacillus species are one of the most frequently used 
probiotic strains in the treatment of gastrointestinal disorders (10) or as therapy for clinical 
conditions such as antibiotic-associated diarrhea (11), VAP (7, 12), sepsis, and postoperative 
infections (13). More specifically, a recent randomized controlled trial of Lactobacillus 
rhamnosus GG (LGG) demonstrated a significant reduction of VAP by 50% in the LGG-
treated group via intention-to-treat analysis (7). Although probiotics appear to show promise 
in various clinical conditions, the mechanisms responsible for their clinical benefit are not 
well understood (14). We have recently shown that LGG administration improves several 
important outcomes in polymicrobial sepsis induced by cecal ligation and puncture in mice 
(15). Based on the results from our previous work and other in vivo and in vitro studies, 
probiotics have been shown to attenuate inflammation (16, 17), reduce the overgrowth of 
pathogenic bacteria, decrease bacterial translocation (18), and reduce apoptosis in intestinal 
epithelial cells (19). Finally, probiotics have been hypothesized to affect T regulatory (Treg) 
cell induction (20, 21). In light of this potential effect of probiotics on Treg cells, very recent 
data propose an immunoregulatory role for Treg cells in containing the excessive 
inflammatory infiltrate from the lung immune response to infection. One potential 
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hypothesis is that excess inflammation following bacterial infection can lead to substantial 
tissue damage through the actions of degradative enzymes and other soluble mediators 
released from the infiltrating immune cells (22). Such tissue damage can worsen lung injury 
and compromise the integrity of the epithelial cell barrier of the lung aiding in bacterial 
dissemination to the bloodstream (22). Supporting this hypothesis, increased Treg cell 
numbers via adoptive transfer techniques have been shown to improve outcome from 
experimental Pneumococcal pneumonia in rodents (22).
Thus, we hypothesize that LGG will reduce lung injury and bronchoalveolar lavage (BAL) 
bacterial count and ultimately improve survival in a Pseudomonas pneumonia model. 
Furthermore, we hypothesize that probiotic administration will attenuate the 
proinflammatory response to the bacterial exposure, and this will be associated with 
increased Treg cell content in the lung.
MATERIALS AND METHODS
Probiotic treatment and pneumonia model
The animal protocol used in these studies was approved by the Institutional Animal Care and 
Use Committee of the University of Colorado Anschutz Medical Campus. An initial power 
analysis on the effect of the probiotic treatments on survival was performed utilizing our 
data studying the same probiotic interventions in a CLP model, which we recently reported 
(15). From our previous experience with this pneumonia model, we expected a similar 
mortality to our CLP model (~90%). In our previous experiments with these probiotic 
treatments, we achieved a mortality reduction of 35% to 40% (15). Thus, using this as an 
initial starting point, we used an SD of 0.4 and determined that the sample size required for 
an α of 0.05 and a power of 80% was 17 to 22 animals per group to detect a mortality 
difference of 35% to 40%. Our pneumonia model utilized 6- to 8-week-old FVB/N mice that 
were orally gavaged with 200 µL of either LGG (1 × 109 colony-forming units [CFUs]/mL) 
or sterile water (vehicle) immediately before procedure. Pneumonia was induced via direct 
intratracheal instillation of Pseudomonas aeruginosa. Under isoflurane anesthesia, mice 
received a midline cervical incision, and P. aeruginosa (ATTC 27853) was introduced into 
the trachea via a 29-gauge syringe. Forty microliters of 4 × 108 CFUs of bacteria diluted in 
sterile saline was used. Mice were then held vertically for 5 s to enhance the delivery into 
the lungs. Sham mice were treated identically except that they received an intratracheal 
injection of saline. All mice received antibiotic therapy (gentamicin 0.2 mg/mL, 
subcutaneously) after the surgery to mimic clinical setting. Animals were killed at either 12 
or 24 h (for acute studies) or followed 7 days for survival. For acute studies, mice received a 
single dose of LGG. For survival studies, mice were treated with LGG daily for 7 days and 
received antibiotic treatment at 0, 12, and 24 h. Note that, for standardization throughout the 
article, control animals not receiving probiotics are referred to as control pneumonia animals 
or pneumonia alone.
LGG culture
Lactobacillus rhamnosus GG (ATCC, Manassas, Va) was incubated in de Man, Rogosa, and 
Sharpe broth (BD, Sparks, Md) for 24 h at 37°C and 5% CO2. A600 was measured to 
Khailova et al. Page 3
Shock. Author manuscript; available in PMC 2017 September 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
determine the number of CFUs per 1 mL. Lactobacillus rhamnosus GG species were 
pelleted from the broth (10,000 revolutions/min [rpm]; 10 min) and resuspended in distilled 
water.
Bacterial cultures
Bronchoalveolar lavage fluid was obtained following tracheal instillation with 1 mL of 
sterile 0.9% saline at 12 h, serially diluted (1:10; 1:100; 1:1,000) in sterile 0.9% saline, and 
cultured on Trypticase soy agar plates with 5% sheep blood (BD) for 24 h at 37°C/5% CO2. 
Colony-forming units were then enumerated for each animal.
Pulmonary pathology and neutrophil infiltration into the lungs
Lung tissue was collected from each animal at 12 h and fixed overnight in 10% formalin, 
paraffin-embedded, and sectioned at 4 to 6 µm. Serial sections were stained with 
hematoxylin-eosin and evaluated for severity of pneumonia by blinded evaluator using a 
grading scale from 0 (no abnormality) to 4 (severe pneumonia) as described previously (23).
Neutrophil infiltration into the lungs was evaluated by staining for myeloperoxidase (MPO). 
After deparaffinization and rehydration, sections were blocked with 1.5% rabbit serum 
(Vector Laboratories, Burlingame, Calif) in phosphate-buffered saline for 30 min, then 
incubated with goat polyclonal MPO (1:50; R&D Systems, Minneapolis, Minn) antibody for 
1 h, washed with phosphate-buffered saline, and incubated with rabbit anti–goat biotinylated 
secondary antibody (Vector Laboratories) for 30 min. Vectastain Elite ABC reagent (Vector 
Laboratories) was then applied, followed by diaminobenzidine as substrate. Sections were 
counterstained with hematoxylin, dehydrated, and cover-slipped. Myeloperoxidase-positive 
cells were quantified in 10 random high-power fields per section. All counting was 
performed by a blinded evaluator.
Serum interleukins 6 and 10 analysis
Enzyme-linked immunosorbent assay (R&D Systems) was used to determine the 
concentrations of interleukin 6 (IL-6) and IL-10 in serum 12-h time point) according to the 
manufacturer’s instructions. Serum was collected after centrifuging blood for 10 min at 
5,000 rpm and stored at −80°C until the assay was performed.
RNA preparation, reverse transcription, and real-time polymerase chain reaction
Total RNA was isolated from lung tissue (snap frozen in liquid N2, collected at 12 h) using 
the RNeasy Plus Mini Kit (Qiagen, Santa Clarita, Calif) as described in the manufacturer’s 
protocol. RNA concentrations were quantified at 260 nm, and the purity and integrity were 
determined using a NanoDrop. Reverse transcription and real-time polymerase chain 
reaction (PCR) assays were performed to quantify steady-state messenger RNA levels of 
Foxp3, IL-6, and IL-10. Complementary DNA was synthesized from 0.2 µg of total RNA. 
Predeveloped TaqMan primers and probes (Applied Biosystems, Foster City, Calif) were 
used for detection. Reporter dye emission was detected by an automated sequence detector 
combined with ABI Prism 7300 Real-Time PCR System (Applied Biosystems). Real-time 
PCR quantification was performed with TaqMan GAPDH controls and relative mRNA 
expression calculated using the 2−ΔΔCT method (24).
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Western blot
For Western blots, lung tissue was harvested and frozen immediately in liquid nitrogen. 
Samples were homogenized with a handheld homogenizer in a 5× volume of ice-cold 
homogenization buffer (Tris HCl, 50 mm; pH, 7.4; NaCl, 100 mm; EDTA, 10 mm; Triton 
X-100, 0.5%) with added protease inhibitors (Roche Diagnostics, Mannheim, Germany). 
The homogenates were centrifuged at 10,000 rpm for 5 min at 4°C, and the supernatant was 
collected. Total protein concentration was quantified using the Bradford protein assay. 
Twenty micrograms of each sample was added to a 1× treatment buffer (0.125 M Tris, pH 
6.8, 4% sodium dodecyl sulfate, 20% glycerol, and 10% β-mercaptoethanol), boiled for 3 
min, and then loaded into a NuPAGE 4% to 12% bis-tris Gel (Invitrogen, Carlsbad, Calif). 
Proteins were electrophoretically separated with a minigel system and transferred to 
polyvinylidine difluoride membranes (Millipore, Billerica, Mass), using the wet transfer 
system (BioRad, Hercules, Calif). Membranes were blocked in 5% nonfat milk in 
phosphate-buffered saline (PBS)–Tween for 1 h at room temperature. Primary antibodies 
against Foxp3 (1:000) (catalog ABE75; EMD Millipore) or β-actin (1:10,000) (Sigma-
Aldrich, St Louis, Mo) were added to antibody buffer (blocking solution) and incubated 
overnight at 4°C. After washing three times with PBS-Tween for 30 min, secondary 
antibodies, peroxidase-conjugated goat anti–mouse or goat anti–rabbit immunoglobulin G 
(Pierce, Rockford, Ill), were applied at a 1:3,000 dilution for 1.5 h. Blots were washed three 
times with PBS-Tween for 30 min, incubated in commercial enhanced chemiluminescence 
reagents (Pierce), and exposed using a UVP chemiluminescent darkroom system (UVP, 
Upland, Calif).
Flow cytometry
For flow cytometry, lungs were perfused with a 2 mM EDTA saline solution and harvested. 
Tissue was minced, digested in collagenase D (Sigma-Aldrich) for 1 h, and ground through 
100-µm cell strainer for staining. After red blood cell lysis, cells were stained with eF-450–
labeled CD4 (catalogRM4-5; eBiosciences, San Diego, Calif) and PerCP-labeled major 
histocompatibility complex class II (catalog M5/114.15.2; Biolegend, San Diego, Calif) for 
30 min at room temperature in the dark, in staining buffer containing the anti-Fc receptor 
blocking antibody 2.4G2. Cells were then fixed, permeabilized, and stained with PE-labeled 
Foxp3 using the Foxp3 staining kit (catalog 00-5523-00; eBiosciences) as per 
manufacturer’s instructions. Cells negative for major histocompatibility complex class II but 
positive for Foxp3 and CD4 were identified as Treg cells. A FACSCanto II (BD) was used 
for flow cytometry acquisition. FlowJo software (TreeStar, Ashland, Ore) was used for data 
analysis.
Statistical analysis
Comparisons were performed with t test analysis (unpaired, two-tailed). Survival studies 
were analyzed via the log-rank test. To analyze the bacterial culture results, two-tailed NPar, 
Mann-Whitney U test was used. No measurements or animals were lost to observation or 
missing in the analysis. Data were analyzed using Prism 4.0 (GraphPad Software, San 
Diego, Calif) and reported as means ± SE. P ≤ 0.05 was considered to be statistically 
significant.
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RESULTS
LGG improves survival in P. aeruginosa–induced pneumonia
To determine if treatment with LGG affected mortality in P. aeruginosa–induced pneumonia, 
separate cohorts of mice (shams n = 4 per group, pneumonia [control] n = 22, pneumonia + 
LGG n = 20) were intratracheally injected with P. aeruginosa and followed 7 days for 
survival and treated with/without LGG (Fig. 1). Mice treated with LGG had significantly 
improved 7-day survival (P < 0.01) compared with control mice with pneumonia (55% vs. 
14%). All sham animals survived.
LGG treatment decreases bacterial counts in BAL fluid
To examine the effect of LGG treatment on bacterial counts in BAL fluid, BAL fluid was 
cultured, and bacteria numbers counted. The data are expressed as CFUs per 1 mL.
Bacterial counts in BAL obtained from mice with pneumonia were significantly increased in 
comparison to shams (P < 0.02). Mice receiving LGG treatment before the surgery had 
significantly lower number of bacteria in BAL fluid versus control animals with pneumonia 
(P < 0.02) (Fig. 2, A and B).
LGG improves pulmonary pathology and normalizes the number of infiltrating neutrophils 
in lungs of mice with pneumonia
To determine whether the improved survival may be related to reduced lung injury, the effect 
of probiotic treatment on lung pathology was assessed. Pseudomonas aeruginosa infection 
caused marked histological injury 12 h after the intratracheal injection in control animals, 
which was significantly improved in animals treated with LGG (Fig. 3, A and B).
Pseudomonas aeruginosa–mediated lung injury was associated with a significantly higher 
number of infiltrating neutrophils, represented by the number of MPO-positive cells in the 
control pneumonia animals when compared with shams (P < 0.01). Treatment with LGG 
normalized (P < 0.01) the number of MPO-positive cells in the lungs to that observed in 
sham mice (Fig. 4).
LGG attenuates systemic inflammatory response during pneumonia
Attenuation of the proinflammatory response has been hypothesized to be a potential 
protective mechanism following probiotic administration (16, 17). To determine the effect of 
LGG on inflammatory markers in P. aeruginosa–induced pneumonia model, serum levels of 
the proinflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10 were measured by 
enzyme-linked immunosorbent assay.
Levels of IL-6 significantly increased in control mice with pneumonia compared with shams 
(P < 0.05), whereas treatment with LGG led to significantly reduced (P < 0.05) systemic 
IL-6 levels compared with untreated pneumonia mice (Fig. 5A).
Serum levels of IL-10 showed increasing trend in pneumonia mice treated with LGG 
compared with untreated pneumonia mice. This change did not reach statistical significance 
(Fig. 5B).
Khailova et al. Page 6
Shock. Author manuscript; available in PMC 2017 September 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
LGG treatment effects mRNA expression of cytokines in lungs of mice with pneumonia
The induction of anti-inflammatory cytokines is thought to be one of protective mechanisms 
following probiotic administration (16). We found the mRNA levels of IL-10 significantly 
increased in the lungs of animals infected with P. aeruginosa and treated with LGG 
compared with control pneumonia mice (P < 0.05) (Fig. 6A).
mRNA levels of proinflammatory cytokine IL-6 were elevated in pneumonia mice and 
showed a trend toward reduced levels in the lungs of mice treated with LGG, although this 
change did not achieve statistical significance (Fig. 6B).
LGG modulates the Treg cell response in lungs of mice with pneumonia
To examine whether LGG regulates Treg cells in the lungs of mice infected with P. 
aeruginosa, mRNA and protein levels of Foxp3 were analyzed. Flow cytometry was used to 
further confirm these results.
Interestingly, treatment with LGG significantly increased gene expression of Foxp3, the 
marker of Treg cells, in mice following pneumonia versus control pneumonia mice at the 12-
h time point (P < 0.05) (Fig. 7A). Protein levels of Foxp3 were not changed at the 12-h time 
point (Fig. 7, B and C) but were significantly elevated in lungs of LGG-treated pneumonia 
mice compared with control pneumonia mice at 24 h after intratracheal injection of P. 
aeruginosa (Fig. 7, D and E). The changes in lung tissue were also confirmed by flow 
cytometry analysis (Fig. 7, F and G) as cells positive for Foxp3 and CD4 significantly 
increased in animals treated with LGG compared with lungs of control pneumonia animals.
DISCUSSION
This study demonstrates that administration of the probiotic bacteria LGG before onset of 
infection leads to significantly improved survival and decreased systemic inflammatory 
response in mice exposed to intratracheal instillation of P. aeruginosa (P. aeruginosa 
pneumonia). This improvement was associated with reduced bacterial counts in BAL in 
LGG-treated mice. Lungs of mice treated with LGG demonstrated reduced histological lung 
injury and lower number of infiltrating neutrophils compared with control pneumonia mice. 
Finally, administration of LGG was associated with increased Treg cell content in the lungs.
Critical illness and its treatment create a hostile environment in the gut, which alters the 
microbiota and can lead to overgrowth of pathogens (25). Oral administration of probiotics 
may modify the gastrointestinal environment and create one that favors the growth of less 
pathogenic species. It is unknown whether probiotic treatment and potential modification of 
the upper aerodigestive microflora could cause reduction of nosocomial infections. Recently 
published data from randomized clinical trials demonstrate that the use of probiotics in 
critically ill patients is a promising preventive strategy against VAP (7, 14), sepsis, and 
postoperative infections (15). It is likely that currently used probiotic strains at their 
recommended doses may require early (preinfection, preoperatively, or at ICU admission) 
and continued administration to have positive effects in critically ill and trauma patients (26–
29). In our pneumonia model, the animals were given LGG at the onset of P. aeruginosa 
infection to better imitate the desired clinical setting of early treatment in mechanically 
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ventilated ICU patients at risk for VAP to prevent progressive infection and sepsis. This 
study demonstrates that oral administration of LGG significantly improves the survival of 
mice infected with P. aeruginosa and reduces bacterial growth in BAL.
Traditionally, Treg cells were felt to lead to immunosuppression, which could potentially 
impair immune defense. This effect could be hypothesized to worsen outcome from an insult 
such as a bacterial infection (22). However, specific to pneumonia, previous work has shown 
that Foxp3 deficiency causes increased lung inflammation in Foxp3mut mice (30). Another 
study has shown an essential role of T cells in clearing acute Streptococcus pneumoniae 
infection when using Rag1−/− mice with innate immunity but no lymphocytes (31). 
Furthermore, very recent data indicate that increased Treg cell numbers via adoptive transfer 
techniques can improve the outcome from experimental pneumonia in rodents (22). In 
regard to this finding, there are at least two types of Treg cells performing similar functions. 
The first type is defined by expression of CD4 and CD25 developing in the thymus under the 
control of Foxp3 transcription factor (32). Second, inducible Treg cells have been identified 
that are generated in the periphery after activation of naive T cells in the presence of 
inflammation. Inducible Treg cells are also able to produce cytokines such as IL-10 that 
regulate inflammation (33). In this report, we show that mRNA levels of Foxp3 in the lungs 
of mice following LGG treatment are significantly increased 12 h after the surgery. Protein 
levels follow this mRNA increase and are elevated at 24 h following the onset of pneumonia. 
This may suggest an involvement of Treg cells in the protective effect of LGG against P. 
aeruginosa infection. Indeed, it is currently unknown if induction of Treg cells from naive T 
cells or naturally occurring Treg cells or both is responsible for this response. Interestingly, 
the mRNA levels of IL-10 were also elevated in the lungs of pneumonia mice receiving 
LGG treatment. It is possible LGG influences the activation of inducible Treg cells, which 
leads to increased levels of anti-inflammatory cytokine IL-10 in the lungs of P. aeruginosa–
infected mice. In support of our findings, a recent clinical study has demonstrated that 
probiotic administration is associated with Foxp3 Treg cell induction and IL-10 secretion in 
human peripheral blood after probiotic administration (21). Further clinical trials have 
shown a significant increase in Foxp3 mRNA expression in ileal biopsies following probiotic 
administration (34).
New findings on the key role of Treg cells in protection against pneumococcal pneumonia 
(22), in conjunction with our initial findings in pseudomonal pneumonia may begin to alter 
our perception of host immune responses to bacterial infection, emphasizing the importance 
of balancing proinflammatory responses in the lung with controlled anti-inflammatory and 
immunomodulatory activity by cells such as Treg cells.
A key limitation of our work at this point is that we cannot make a direct mechanistic link 
between improved outcomes following LGG administration and Treg cell induction. In 
future studies, we plan to examine the specific role of Treg cells in LGG-mediated 
protection against pneumonia.
In conclusion, infections (and specifically respiratory infections) continue to be a major 
cause of mortality and morbidity in ICUs worldwide (2). Furthermore, with the majority of 
ICU patients receiving antibiotics, derangement of the normal microbiome and potential 
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overgrowth of drug-resistant pathogenic bacterial strains continue to be a significant issue. 
The potential for the restoration of “healthy” microbiome flora via administration of 
probiotics to restore appropriate balance to the gut microbiome and the immune response to 
infection could have significant therapeutic effects. Our data show that early administration 
of LGG before tracheal instillation of P. aeruginosa improves survival, reduces bacteremia 
and BAL bacterial content, and reduces lung injury. From a clinical perspective, probiotic 
treatment significantly reduced the acquisition of “clinical” pneumonia following exposure 
to an otherwise lethal P. aeruginosa exposure. This effect may in part be mediated by an 
influence on the lung immune response to infection, including upregulation of Treg cells. 
Future research is needed to further explore the connection between probiotics and Treg cell 
induction in infection and critical illness.
We believe our data add to a growing body of existing clinical trial and mechanistic data 
supporting the potential efficacy of probiotics in critical illness. The broad clinical 
application of probiotics in the ICU and other clinical areas has recently been limited by 
concerns regarding safety and potential increased risk of infection from probiotic 
administration. Although we did not specifically evaluate for bacteremia from our 
administered probiotic strains, we did observe a marked and statistically significant 
reduction in mortality in our animals treated with live probiotic bacteria. Furthermore, the 
results of the recent American Health Care Research and Quality report on the safety of 
probiotic therapy in more than 600 published clinical trials and case reports are quite 
reassuring with regard to the safety of probiotic administration (35). One recent clinical trial 
studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected 
increase in mortality in probiotic-treated patients (36). This trial was unique as it 
administered multiple stains of probiotic bacteria and prebiotic-like fiber via a postpyloric 
feeding tube (placed in the small bowel). This postpyloric method of administration was 
associated with an increase in small bowel necrosis, which was subsequently associated with 
death in a number of patients receiving the prebiotic fiber/probiotic mixture. It has been 
hypothesized that the postpyloric administration of this fiber/multiple probiotic strain 
mixture in pancreatitis patients may carry significant risk and should likely be avoided (37). 
In any case, careful and appropriate safety monitoring in all future probiotic clinical trials 
should be conducted, specific patient groups should be excluded or studied with great 
caution (i.e., prosthetic heart valve patients), and probiotic administration should be confined 
to widely studied and thus far safe oral and gastric administration. It is likely the time has 
come to proceed with carefully designed, carefully monitored, multicenter randomized 
clinical trials of probiotic therapy to attempt to reduce the risk of infection, sepsis, and 
mortality in critically ill children and adults. In closing, the use of probiotic bacteria in 
critically ill patients alongside traditional antibiotic therapies has the potential to be an ideal 
and cost-effective strategy to prevent hospital-acquired infections, such as VAP, and 
maintain appropriate immune “balance.”
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Fig. 1. 
Effect of LGG treatment on mortality in P. aeruginosa pneumonia. Six- to 8-week-old 
FVB/N mice were subjected to P. aeruginosa–induced pneumonia with or without probiotic 
(LGG) treatment that was initiated immediately before surgery. Sham animals received 
intratracheal injections of saline. All mice were given antibiotics at 0, 12, and 24 h and 
probiotic treatment every 12 h and followed for survival for 7 days. Mice treated with LGG 
had significantly decreased mortality (P < 0.01) compared with control mice with 
pneumonia (pneumonia alone) (55% vs. 14%). Shams n = 4 per group, pneumonia n = 22, 
pneumonia + LGG n = 20. All sham mice survived.
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Fig. 2. 
Effect of LGG treatment on BAL cultures in P. aeruginosa pneumonia at 12 h. A, Mice with 
pneumonia had significantly increased bacterial count in BAL compared with shams (P < 
0.02), whereas mice treated with LGG had significantly reduced bacterial load in the BAL 
(P < 0.02). Shams n = 3 to 4 per group, pneumonia, pneumonia + LGG n = 6 to 7 per group. 
Data are expressed as the mean ± SE. B, Bacterial growth on representative TSA plates with 
sheep blood (5%) for pneumonia and pneumonia + LGG groups is shown.
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Fig. 3. Effect of LGG treatment on pulmonary pathology at 12 h
A, The severity of pneumonia (from 0: no abnormality to 4: severe pneumonia) was 
significantly reduced in the lungs of mice treated with LGG (P < 0.02). B, Representative 
hematoxylin-eosin–stained sections of lung are shown. Original magnification ×100. Shams 
n = 4 per group, pneumonia, pneumonia + LGG n = 8 to 10 per group.
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Fig. 4. Effect of LGG treatment on neutrophil infiltration at 12 h
Numbers of MPO-positive cells were enumerated in the lung to evaluate the neutrophil 
infiltration. Mice with pneumonia had significantly higher number of MPO-positive cells in 
comparison to shams (P < 0.01). Lactobacillus rhamnosus GG treatment significantly 
decreased the neutrophil infiltration into the lung (P < 0.01). Shams n = 4 per group, 
pneumonia, pneumonia + LGG n = 8 to 10 per group.
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Fig. 5. Effect of LGG treatment on the systemic inflammatory response at 12 h
Enzyme-linked immunosorbent assay was used to determine the concentrations of IL-6 and 
IL-10 in serum. A, Interleukin 6 was significantly elevated in the serum of mice with 
pneumonia compared with shams (P < 0.01). Treatment with LGG in pneumonia mice led to 
significantly reduced systemic IL-6 levels (P < 0.05) compared with control mice with 
pneumonia. B, Serum levels of IL-10 showed increasing trend in pneumonia mice treated 
with LGG compared with untreated pneumonia mice. The change has not reached 
significance. Shams n = 4 to 5 per group; pneumonia, pneumonia + LGG n = 6 to 12 per 
group. Data are expressed as the mean ± SE.
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Fig. 6. Effect of LGG treatment on IL-10 and IL-6 expression in the lungs at 12 h
Reverse transcription and real-time PCR assays were performed to quantify steady-state 
mRNA levels of IL-6 and IL-10. A, Lactobacillus rhamnosus GG treatment significantly 
increased the gene expression of IL-10 in the lungs of pneumonia mice compared with all 
other experimental groups (P < 0.05). B, mRNA levels of proinflammatory cytokine IL-6 
were elevated in control pneumonia mice and decreased in the lungs of mice treated with 
LGG, although this change has not reached significance. Shams n = 3 to 4 per group; 
pneumonia, pneumonia + LGG n = 5 to 7 per group. Data are expressed as the mean ± SE.
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Fig. 7. Effect of LGG treatment on T cells in the lungs at 12 and 24 h
A, Reverse transcription and real-time PCR assays were performed to quantify steady-state 
mRNA levels of Foxp3 at 12 h. Gene expression of Foxp3 was significantly increased in 
pneumonia mice receiving LGG treatment compared with control pneumonia animals (P < 
0.05). Shams n = 3 to 4 per group; pneumonia, pneumonia + LGG n = 5 to 7 per group. Data 
are expressed as the mean ± SE. B and C, Protein levels of Foxp3 analyzed by Western blot 
have not changed at the 12-h time point. D and E, Twenty-four hours after intratracheal 
injection of P. aeruginosa, Foxp3 levels were significantly elevated in lungs of LGG-treated 
pneumonia mice compared with control pneumonia mice (shams, n = 3 per group; 
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pneumonia, n = 8; pneumonia + LGG, n = 5). F and G, CD4+ Foxp3+ cells were 
significantly increased in lungs of LGG-treated pneumonia mice compared with control 
pneumonia mice (P < 0.05). Representative zebra plots showing outliers, using log10 scales 
for each group, are shown (shams, n = 2 per group; pneumonia, n = 7; pneumonia + LGG, n 
= 8).
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